GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMO) » Definitions » Free Cash Flow

Avid Bioservices (Avid Bioservices) Free Cash Flow : $-38.5 Mil (TTM As of Jan. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Avid Bioservices Free Cash Flow?

Avid Bioservices's total free cash flow for the months ended in Jan. 2024 was $-0.8 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Jan. 2024 was $-38.5 Mil.

Avid Bioservices's Free Cash Flow per Share for the months ended in Jan. 2024 was $-0.01. Its free cash flow per share for the trailing twelve months (TTM) ended in Jan. 2024 was $-0.61.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.

During the past 13 years, Avid Bioservices's highest 3-Year average Free Cash Flow per Share Growth Rate was 47.00% per year. The lowest was -62.90% per year. And the median was 8.40% per year.


Avid Bioservices Free Cash Flow Historical Data

The historical data trend for Avid Bioservices's Free Cash Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices Free Cash Flow Chart

Avid Bioservices Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Free Cash Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.10 2.02 21.32 -46.95 -90.53

Avid Bioservices Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Free Cash Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.24 -22.08 -14.39 -1.22 -0.80

Avid Bioservices Free Cash Flow Calculation

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Avid Bioservices's Free Cash Flow for the fiscal year that ended in Apr. 2023 is calculated as

Free Cash Flow (A: Apr. 2023 )=Cash Flow from Operations+Capital Expenditure
=-12.887+-77.638
=-90.5

Avid Bioservices's Free Cash Flow for the quarter that ended in Jan. 2024 is calculated as

Free Cash Flow (Q: Jan. 2024 )=Cash Flow from Operations+Capital Expenditure
=3.687+-4.488
=-0.8

Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avid Bioservices  (NAS:CDMO) Free Cash Flow Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Jan24, Avid Bioservices's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Jan24)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/6.77+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


Avid Bioservices Free Cash Flow Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Avid Bioservices (Avid Bioservices) Business Description

Traded in Other Exchanges
Address
14191 Myford Road, Tustin, CA, USA, 92780
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
Executives
Matthew R. Kwietniak officer: Chief Commercial Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Richard A. Richieri officer: Chief Operations Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Daniel Ryan Hart officer: Chief Financial Officer 2642 MICHELLE DR., SUITE 200, TUSTIN CA 62780
Mark R Ziebell officer: V.P., General Counsel 14282 FRANKLIN AVENUE, TUSTIN CA 92780
Richard B Hancock director 14282 FRANKLIN AVE., TUSTIN CA 92780
Joseph Carleone director 3883 HOWARD HUGHES PKWY, SUITE 700, LAS VEGAS NV 89169
Nicholas Stewart Green director, officer: President & CEO 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Gregory Sargen director
Esther M. Alegria director 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Mark R Bamforth director 500 KENDALL ST., CAMBRIDGE MA 02142
Jeanne Thoma director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Joel Mccomb director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Stephen Michael Hedberg officer: Principal Fin. & Acct. Officer 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780

Avid Bioservices (Avid Bioservices) Headlines

From GuruFocus

Avid Bioservices Appoints Oksana Lukash as Vice President, People

By Value_Insider Value_Insider 11-16-2022